前蛋白转化酶枯草溶菌素Kexin 9型抑制剂在缺血性卒中治疗中的研究进展

doi:10.3969/j.issn.1673-5765.2021.08.017

摘要/Abstract

摘要： 血脂异常与动脉粥样硬化的发展及缺血性卒中事件的发生有密切关联，较低水平的 LDL-C可以有效降低心脑血管疾病风险。前蛋白转化酶枯草溶菌素Kexin 9型（proprotein convertase subtilisin/kexin type 9，PCSK9）是一种全新的降低LDL-C的治疗靶点，PCSK9抑制剂可以显著降低血液中LDL-C水平，并可延缓动脉粥样硬化进程。临床研究表明使用PCSK9抑制剂的患者动脉粥样硬化性心血管疾病和缺血性卒中事件发生率显著降低；另外，PCSK9基因多态性与高胆固醇血症、动脉粥样硬化及缺血性卒中密切相关。

文章导读： 本文主要介绍了PCSK9抑制剂在缺血性卒中治疗中的研究进展，PCSK9抑制剂不仅可以降低LDL-C水平及缺血性卒中风险，且安全性良好，并未增加出血性卒中风险。

关键词: 前蛋白转化酶枯草溶菌素Kexin 9型抑制剂; 缺血性卒中; 低密度脂蛋白胆固醇; 脂质代谢; 基因多态性

Abstract: Dyslipidemia is closely related to atherosclerosis development and ischemic stroke, and lower level of LDL-C can effectively reduce the risk of cardiovascular and cerebrovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK 9) is a novel therapeutic target for reducing LDL-C level. PCSK 9 inhibitors can significantly reduce the level of LDL-C, and inhibit the progression of atherosclerosis. Clinical studies have shown that the PCSK9 inhibitors can significantly reduce the incidence of atherosclerotic cardiovascular events and ischemic stroke, and the genetic polymorphism of PCSK9 is closely related to hypercholesterolemia, atherosclerosis and ischemic stroke.

Key words: Proprotein convertase subtilisin/kexin type 9 inhibitor; Ischemic stroke; Lowdensity lipoprotein cholesterol; Lipid metabolism; Gene polymorphism

邓奇乐, 吴介洪, 陈吉相. 前蛋白转化酶枯草溶菌素Kexin 9型抑制剂在缺血性卒中治疗中的研究进展[J]. 中国卒中杂志, 2021, 16(08): 850-854.

DENG Qi-Le, WU Jie-Hong, CHEN Ji-Xiang. Progress of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in the Treatment of Ischemic Stroke[J]. Chinese Journal of Stroke, 2021, 16(08): 850-854.

参考文献

[1] TAN Y F，ZHAN L X，CHEN X H，et al. Risk
factors，clinical features and prognosis for subtypes
of ischemic stroke in a Chinese population[J]. Curr
Med Sci，2018，38（2）：296-303.
[2] BRAUTBAR A，BALLANTYNE C M.
Pharmacological strategies for lowering LDL
cholesterol：statins and beyond[J]. Nat Rev Cardiol，
2011，8（5）：253-265.
[3] STROES E S，THOMPSON P D，CORSINI A，et
al. Statin-associated muscle symptoms：impact on
statin therapy-European Atherosclerosis Society
Consensus Panel statement on assessment，aetiology
and management[J]. Eur Heart J，2015，36（17）：
1012-1022.
[4] JUKEMA J W，ZIJLSTRA L E，BHATT D L，et
al. Effect of alirocumab on stroke in ODYSSEY
OUTCOMES[J]. Circulation，2019，140（25）：2054-
2062.
[5] SEIDAH N G，BENJANNET S，WICKHAM L，
et al. The secretory proprotein convertase neural
apoptosis-regulated convertase 1（NARC-1）：liver
regeneration and neuronal differentiation[J]. Proc
Natl Acad Sci USA，2003，100（3）：928-933.
[6] LIU M H. Antihyperlipidemic therapies targeting
PCSK9：novel therapeutic agents for lowering lowdensity
lipoprotein cholesterol[J/OL]. Int J Cardiol，
2015，195：212-214[2021-03-01]. https：//doi.
org/10.1016/j.ijcard.2015.05.150.
[7] KWON H J，LAGACE T A，MCNUTT M C，et al.
Molecular basis for LDL receptor recognition by
PCSK9[J]. Proc Natl Acad Sci USA，2008，105（6）：
1820-1825.
[8] RASHID S，CURTIS D E，GARUTI R，et al.
Decreased plasma cholesterol and hypersensitivity
to statins in mice lacking PCSK9[J]. Proc Natl Acad
Sci USA，2005，102（15）：5374-5379.
[9] BLASIOLE D A，OLER A T，ATTIE A D.
Regulation of ApoB secretion by the low density
lipoprotein receptor requires exit from the
endoplasmic reticulum and interaction with ApoE or
ApoB[J]. J Biol Chem，2008，283（17）：11374-11381.
[10] TWISK J，GILLIAN-DANIEL D L，TEBON A，et
al. The role of the LDL receptor in apolipoprotein B
secretion[J]. J Clin Invest，2000，105（4）：521-532.
[11] LAMBERT G，JARNOUX A L，PINEAU T，et
al. Fasting induces hyperlipidemia in mice
overexpressing proprotein convertase subtilisin
kexin type 9：lack of modulation of very-lowdensity
lipoprotein hepatic output by the low-density
lipoprotein receptor[J]. Endocrinology，2006，147
（10）：4985-4995.
[12] HERBERT B，PATEL D，WADDINGTON S N，et
al. Increased secretion of lipoproteins in transgenic
mice expressing human D374Y PCSK9 under
physiological genetic control[J]. Arterioscler Thromb
Vasc Biol，2010，30（7）：1333-1339.
[13] SUN H，SAMARGHANDI A，ZHANG N，et
al. Proprotein convertase subtilisin/kexin type 9
interacts with apolipoprotein B and prevents its
intracellular degradation，irrespective of the lowdensity
lipoprotein receptor[J]. Arterioscler Thromb
Vasc Biol，2012，32（7）：1585-1595.
[14] LAGACE T A. PCSK9 and LDLR degradation：
regulatory mechanisms in circulation and in cells[J].
Curr Opin Lipidol，2014，25（5）：387-393.
[15] OOI T C，KRYSA J A，CHAKER S，et al. The
effect of PCSK9 loss-of-function variants on the
postprandial lipid and ApoB-lipoprotein response[J].
J Clin Endocrinol Metab，2017，102（9）：3452-3460.
[16] ABIFADEL M，RABÈS J P，BOILEAU C，et
al. After the LDL receptor and apolipoprotein B，
autosomal dominant hypercholesterolemia reveals
its third protagonist：PCSK9[J]. Ann Endocrinol
（Paris），2007，68（2/3）：138-146.
[17] ABBOUD S，KARHUNEN P J，LÜTJOHANN
D，et al. Proprotein convertase subtilisin/kexin
type 9（PCSK9）gene is a risk factor of large-vessel
atherosclerosis stroke[J/OL]. PLoS One，2007，2
（10）：e1043[2021-03-01]. https：//doi.org/10.1371/
journal.pone.0001043.
[18] RAO A S，LINDHOLM D，RIVAS M A，et al.
Large-scale phenome-wide association study of
PCSK9 variants demonstrates protection against
ischemic stroke[J/OL]. Circ Genom Precis Med，
2018，11（7）：e002162[2021-03-01]. https：//doi.
org/10.1161/circgen.118.002162.
[19] AUNG L H，YIN R X，MIAO L，et al. The
proprotein convertase subtilisin/kexin type 9 gene
E670G polymorphism and serum lipid levels in the
Guangxi Bai Ku Yao and Han populations[J/OL].
Lipids Health Dis，2011，10：5[2021-03-01].
https：//doi.org/10.1186/1476-511x-10-5.
[20] KEREIAKES D J，ROBINSON J G，CANNON C P，
et al. Efficacy and safety of the proprotein convertase
subtilisin/kexin type 9 inhibitor alirocumab among
high cardiovascular risk patients on maximally
tolerated statin therapy：the ODYSSEY COMBO I
study[J]. Am Heart J，2015，169（6）：906-915.
[21] HAN D F，MA J H，ZHANG X N，et al. Correlation
of PCSK9 gene polymorphism with cerebral

ischemic stroke in Xinjiang Han and Uygur

populations[J/OL]. Med Sci Monit，2014，20：1758-
1767[2021-03-01]. https：//doi.org/10.12659/
msm.892091.
[22] WICIŃSKI M，ŻAK J，MALINOWSKI B，et
al. PCSK9 signaling pathways and their potential
importance in clinical practice[J]. EPMA J，2017，8
（4）：391-402.
[23] RIDKER P M，REVKIN J，AMARENCO P，et al.
Cardiovascular efficacy and safety of bococizumab
in high-risk patients[J]. N Engl J Med，2017，376
（16）：1527-1539.
[24] JEONG H J，LEE H S，KIM K S，et al. Steroldependent
regulation of proprotein convertase
subtilisin/kexin type 9 expression by sterolregulatory
element binding protein-2[J]. J Lipid Res，
2008，49（2）：399-409.
[25] SABATINE M S，GIUGLIANO R P，WIVIOTT S D，
et al. Efficacy and safety of evolocumab in reducing
lipids and cardiovascular events[J]. N Engl J Med，
2015，372（16）：1500-1509.
[26] SABATINE M S，GIUGLIANO R P，KEECH A C，
et al. Evolocumab and clinical outcomes in patients
with cardiovascular disease[J]. N Engl J Med，2017，
376（18）：1713-1722.
[27] SCHWARTZ G G，STEG P G，SZAREK M，et al.
Alirocumab and cardiovascular outcomes after acute
coronary syndrome[J]. N Engl J Med，2018，379
（22）：2097-2107.
[28] ZHANG X L，ZHU Q Q，ZHU L，et al. Safety and
efficacy of anti-PCSK9 antibodies：a meta-analysis
of 25 randomized，controlled trials[J/OL]. BMC Med，
2015，13：123[2021-03-01]. https：//doi.org/10.1186/
s12916-015-0358-8.
[29] TOTH P P，WORTHY G，GANDRA S R，et al.
Systematic review and Network meta-analysis on the
efficacy of evolocumab and other therapies for the
management of lipid levels in hyperlipidemia[J/OL].
J Am Heart Assoc，2017，6（10）：e005367[2021-03-
01]. https：//doi.org/10.1161/jaha.116.005367.
[30] GIUGLIANO R P，PEDERSEN T R，SAVER J L，et
al. Stroke prevention with the PCSK9（proprotein
convertase subtilisin-kexin type 9）inhibitor
evolocumab added to statin in high-risk patients
with stable atherosclerosis[J]. Stroke，2020，51（5）：
1546-1554.
[31] ALBERTS M J，THOMPSON P D. PCSK9
（proprotein convertase subtilisin-kexin type
9）inhibition and stroke prevention：another step
forward[J]. Stroke，2020，51（5）：1361-1362.
[32] CHAPMAN M J，GINSBERG H N. Evolocumab
treatment of hypercholesterolemia in OSLER-1：
enduring efficacy，tolerability，and safety over 5
years[J]. J Am Coll Cardiol，2019，74（17）：2147-
2149.
[33] 王拥军，李子孝，徐安定，等. 前蛋白转化酶枯草溶
菌素Kexin 9型抑制剂在缺血性卒中二级预防中的
临床应用专家共识[J]. 中国卒中杂志，2019，14（6）：
594-599.